Development of a novel and efficient chemo-enzymatic route for the synthesis of liraglutide and semaglutide based on a fragment condesation approach using EnzyPep’s ligation technology.
Pharmaceutical peptides can be efficiently ligated to large proteins such as human serum albumin and to polymers (XTEN) of more than 850 amino acids in length.
The board of Enzypep approved a new financing for 2015 – 2017 of over 4 million Euro via the existing shareholders together with RVO (Innovation Credit).
Huge improvements from R&D on enzymatic ligation technology. Broad IP platform created.
Assembled highly experienced international scientific advisory board.
Founded: July 2012 (based on exclusive IP obtained from DSM, generated during 8 years R&D)
Investors: Founder, Limburg Ventures, Chemelot Ventures, Nedermaas Ventures.